01.05.2023 | Tracker

Product Launch Tracker: HCPs are captivated by the approval of Vowst, a faecal microbiota product.

By Alexandra Maria Chatziioannidou

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout April 2023 we tracked the global conversations of 1,781 eHCPs who posted 2,572 English-language Twitter posts about the launches and approvals of new products.

In April, several product approvals were discussed online by HCPs. They offered their thoughts on a novel treatment for an alternative combination medications for previously untreated large B-cell lymphoma (DLBCL).

One of the approvals which generated significant conversation among HCPs was the FDA approval of Vowst, as the first oral medication faecal microbiota product to prevent clostridioides difficile recurrence (CDI). HCPs posted positive opinions on this approval marking it as “big news”. HCPs considered this a significant breakthrough, beyond just the infectious disease space, suggesting that the technology may also lead to advancements in the treatment of cancer. 

On 26 March an important FDA Accelerated Approval activated the HCP online conversation. The FDA approved Qalsody (tofersen) for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). The medication which is manufactured by Biogen generated excitement from the HCPs quoting “a great moment for the ASL community” and “a tremendous achievement”.

Later in the month, the FDA approved Polivy (polatuzumab vedotin-piiq) by Genetech Int. paired with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). This combination is indicated for patients who have Diffuse large B-cell lymphoma (DLBCL) which have been untreated in the past. It is also indicated for patients with high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. HCPs shared their positive views on the approval describing as “landmark decision by the FDA”. HCPs also congratulated their peers behind the science of this drug and the trial, being hopeful for the change and benefits that will bring to the patients. 

On April 17th, a modified allogeneic cord blood-based cell therapy, Omisirge (omidubicel-onlv), was approved by the FDA. The medication brought by Gamida Cell is responsible for quickening the recovery of a group of white blood cells called neutrophils which reduce infection risks. The medication is indicated for patients with blood cancers planned for umbilical cord blood transplantation following myeloablative conditioning regimen. HCPs were quick to share the news online, including those who took part in the trial. HCPs were delighted about the first allogeneic cell therapy to be approved and congratulated their peers for their achievement.

In early April, the FDA granted Accelerated Approval to Astellas’ Padcev (enfortumab vedotin-ejfv)  in combination with Merck’s Keytruda (pembrolizumab). The medication is indicated for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. HCPs were quick to share the news, expressing their excitement to see how it will perform and described the approval as huge wins for patients”. 

The three most shared links from HCPs discussing product launches in March were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 April and 30 April 2023 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 April and 30 April 2023, there were 2,570 HCP mentions of new pharmaceutical product launches and drug approvals from 1,779  unique HCP authors from around the world. 

Click here to read the latest product launch tracker

View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next

01.04.2023 | Article

Product Launch Tracker: HCPs are enthusiastic about the approval of two nasal sprays and an antifungal treatment.

Discover which new drug approvals HCPs are talking about

By Alexandra Maria Chatziioannidou

31.01.2023 | Article

The divided UK eHCP opinions on Medical Cannabis

Many see medical cannabis as an alternative medicine to relieve some patients symptoms

By Mark Sullivan

View all articles >